Rallybio’s Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets
Rallybio Corporation (NASDAQ:RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune…